| 5.3 0.47 (9.73%) | 05-14 12:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.83 | 1-year : | 7.8 |
| Resists | First : | 5.85 | Second : | 6.67 |
| Pivot price | 5.33  |
|||
| Supports | First : | 4.51 | Second : | 3.76 |
| MAs | MA(5) : | 4.93 |
MA(20) : | 5.58 |
| MA(100) : | 7.94 |
MA(250) : | 5.7 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 23.7 |
D(3) : | 13.6 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 11.88 | Low : | 2.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KLRS ] has closed above bottom band by 45.8%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.91 - 4.93 | 4.93 - 4.96 |
| Low: | 4.47 - 4.49 | 4.49 - 4.51 |
| Close: | 4.79 - 4.82 | 4.82 - 4.86 |
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Thu, 14 May 2026
Wedbush Initiates Kalaris Therapeutics at Outperform With $17 Price Target - marketscreener.com
Wed, 13 May 2026
Citizens cuts Kalaris stock price target on manufacturing progress By Investing.com - Investing.com South Africa
Tue, 12 May 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates - Investing News Network
Tue, 12 May 2026
Kalaris Therapeutics posts smaller-than-expected Q1 net loss - TradingView
Tue, 12 May 2026
Kalaris Therapeutics (KLRS) posts Q1 2026 loss with $104.9M cash to fund trials into 2027 - Stock Titan
Tue, 12 May 2026
Eye drug TH103 nears dosing as Kalaris funds trials into 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 10.2 (%) |
| Held by Institutions | 78.6 (%) |
| Shares Short | 843 (K) |
| Shares Short P.Month | 919 (K) |
| EPS | -2.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.2 % |
| Return on Equity (ttm) | -308.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -1.85 |
| PEG Ratio | 0 |
| Price to Book value | 1.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|